The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice. This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.
Nominations for EGAPP Working Group membership are accepted on a continuous basis.
What's New
- The EGAPP Working Group has published a new article entitled “The EGAPP Initiative: Lessons Learned”
- The last EWG meeting was on August 19 and 20, 2013.
- The EGAPP Working Group has published a new article entitled“Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies”
(PDF 656KB) in collaboration with Kaiser Permanente Center for Health Research.
- The EWG has published a newrecommendation on Type 2 Diabetes Risk Prediction
EGAPP Recommendations
- Prostate Cancer: Does PCA3 Testing for the Diagnosis and Management of Prostate Cancer...
- Diabetes: Does genomic profiling to assess Type 2 Diabetes risk improve...
- Colorectal Cancer: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes...
- Cardiovascular Health: Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
- Breast Cancer: Can tumor gene expression profiling improve outcomes…
- Cardiovascular Health: Genomic profiling to assess cardiovascular risk to improve cardiovascular health…
- Colorectal Cancer (Lynch syndrome): Genetic testing strategies in newly diagnosed individuals…
- Colorectal Cancer: Can UGT1A1 genotyping reduce morbidity and mortality…
- Depression: Testing for cytochrome P450 polymorphisms in adults…
.png)
No hay comentarios:
Publicar un comentario